Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer

被引：7

作者：

Woodford, Rachel ^{[1
]}

Loh, Yanni ^{[1
]}

Lee, Joanna ^{[1
]}

Cooper, Wendy ^{[2
,3
,4
]}

Marschner, Ian ^{[5
,6
]}

Lewis, Craig R. ^{[7
]}

Millward, Michael ^{[8
,9
]}

Lord, Sally ^{[5
,10
]}

Gralla, Richard J. ^{[11
]}

Yang, James C-H ^{[12
,13
]}

Mok, Tony ^{[14
]}

Lee, Chee K. ^{[1
,5
]}

机构：

[1] St George Hosp, Canc Care Ctr, Sydney, NSW 2217, Australia

[2] Royal Prince Alfred Hosp, Tissue Pathol & Diagnost Oncol, Sydney, NSW 2050, Australia

[3] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia

[4] Western Sydney Univ, Sch Med, Sydney, NSW 2751, Australia

[5] Univ Sydney, Natl Hlth & Med Res Council, Clin Trials Ctr, Sydney, NSW 1450, Australia

[6] Macquarie Univ, Dept Stat, Sydney, NSW 2109, Australia

[7] Univ NSW, Prince Wales Hosp, Clin Sch, Sydney, NSW 2031, Australia

[8] Univ Western Australia, Sch Med, Perth, WA 6009, Australia

[9] Sir Charles Gairdner Hosp, Dept Med Oncol, Perth, WA 6010, Australia

[10] Univ Notre Dame, Sch Med, Sydney, NSW 2010, Australia

[11] Albert Einstein Coll Med, Jacobi Med Ctr, Bronx, NY 10461 USA

[12] Natl Taiwan Univ, Grad Inst Oncol, Taipei 10002, Taiwan

[13] Natl Taiwan Univ Hosp, Dept Oncol, Taipei 10002, Taiwan

[14] Chinese Univ Hong Kong, Hong Kong Canc Inst, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China

来源：

FUTURE ONCOLOGY | 2019年 / 15卷 / 20期

关键词：

chemoimmunotherapy; meta-analysis; non-small-cell lung cancer; PD-L1; expression; progression-free survival; AMERICAN SOCIETY; SQUAMOUS-CELL; OPEN-LABEL; NIVOLUMAB; CHEMOTHERAPY; DOCETAXEL; IMMUNOHISTOCHEMISTRY; PEMBROLIZUMAB; MECHANISMS; PHASE-1;

D O I：

10.2217/fon-2019-0105

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT versus chemotherapy identified through electronic searches. In seven randomized controlled trials (n =4170), CIT prolonged progression-free survival over chemotherapy (hazard ratio [HR]: 0.62; 95% CI: 0.58-0.67; p < 0.00001). The treatment benefits differed between PD-L1-high (HR: 0.41; 95% CI: 0.34-0.49) and PD-L1 low (HR: 0.63; 95% CI: 0.55-0.72; interaction-p = 0.00002) and PD-L1-high and PD-L1-negative (HR: 0.72; 95% CI: 0.65-0.80; interaction-p < 0.00001). Similar benefits were observed regardless of gender, EGFR/ALK status and histological subtype. PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.

引用

页码：2371 / 2383

页数：13

共 50 条

[21] Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer [J].

Li, Jia-Xin ;

Huang, Ju-Min ;

Jiang, Ze-Bo ;

Li, Run-Ze ;

Sun, Ao ;

Leung, Elaine Lai-Han ;

Yan, Pei-Yu .

INTEGRATIVE CANCER THERAPIES, 2019, 18

[22] Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm [J].

Banna, Giuseppe Luigi ;

Cantale, Ornella ;

Bersanelli, Melissa ;

Del Re, Marzia ;

Friedlaender, Alex ;

Cortellini, Alessio ;

Addeo, Alfredo .

ONCOLOGY REVIEWS, 2020, 14 (02) :135-143

[23] Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) [J].

Incorvaia, Lorena ;

Fanale, Daniele ;

Badalamenti, Giuseppe ;

Barraco, Nadia ;

Bono, Marco ;

Corsini, Lidia Rita ;

Galvano, Antonio ;

Gristina, Valerio ;

Listi, Angela ;

Vieni, Salvatore ;

Gori, Stefania ;

Bazan, Viviana ;

Russo, Antonio .

ADVANCES IN THERAPY, 2019, 36 (10) :2600-2617

[24] Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer [J].

Inoue, Yusuke ;

Yoshimura, Katsuhiro ;

Mori, Kazutaka ;

Kurabe, Nobuya ;

Kahyo, Tomoaki ;

Mori, Hiroki ;

Kawase, Akikazu ;

Tanahashi, Masayuki ;

Ogawa, Hiroshi ;

Inui, Naoki ;

Funai, Kazuhito ;

Shinmura, Kazuya ;

Niwa, Hiroshi ;

Suda, Takafumi ;

Sugimura, Haruhiko .

ONCOTARGET, 2016, 7 (22) :32113-32128

[25] PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis [J].

Garcia Campelo, Maria Rosario ;

Arriola, Edurne ;

Campos Balea, Begona ;

Lopez-Brea, Marta ;

Fuentes-Pradera, Jose ;

de Castro Carpeno, Javier ;

Aguado, Carlos ;

Perez Parente, Diego ;

de Oro Pulido, Fidel ;

Ruiz-Gracia, Pedro ;

Rodriguez-Abreu, Delvys .

JOURNAL OF CLINICAL MEDICINE, 2021, 10 (19)

[26] Frontline anti-PD-1/PD-L1 versus bevacizumab in advanced non-small-cell lung cancer: a network meta-analysis [J].

Chen, Jiarui ;

Liu, Xingyu ;

Zhang, Junhong ;

Huang, Zhao ;

Zeng, Wei ;

Hu, Jing ;

Chen, Gang ;

Gong, Yan ;

Liu, Yu ;

Xie, Conghua .

FUTURE ONCOLOGY, 2022, 18 (13) :1651-1664

[27] The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer [J].

Zhu, Qian ;

Hu, Hao ;

Ouyang, Li-Ying ;

Yang, Rong ;

Wei, Wen-Xiao ;

Huang, Pin ;

He, Xin-Rong .

BMC CANCER, 2025, 25 (01)

[28] PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer [J].

Larsen, Trine Vilsboll ;

Hussmann, Dianna ;

Niesen, Anders Lade .

CANCER COMMUNICATIONS, 2019, 39

[29] PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions [J].

Xia, Liliang ;

Liu, Yuanyong ;

Wang, Ying .

ONCOLOGIST, 2019, 24 :S31-S41

[30] Challenges of PD-L1 testing in non-small cell lung cancer and beyond [J].

Wang, Minyu ;

Wang, Sen ;

Trapani, Joseph A. ;

Neeson, Paul J. .

JOURNAL OF THORACIC DISEASE, 2020, 12 (08) :4541-4548

← 1 2 3 4 5 →